Searchable abstracts of presentations at key conferences in endocrinology

ea0038p208 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Bile acids stimulate GLP-1 release predominantly by accessing basolateral GPBAR1 (TGR5)

Brighton Cheryl A , Rievaj Juraj , Kuhre Rune E , Glass Leslie L , Holst Jens J , Gribble Fiona M , Reimann Frank

Background: Glucagon-like peptide 1 (GLP-1) is an incretin hormone released from enteroendocrine L-cells in the gut. GLP-1 analogues and dipeptidyl-peptidase-4 inhibitors are currently used to treat type-2 diabetes. A greater understanding of the mechanisms underlying the release of GLP-1 may facilitate the development of therapeutics to stimulate the release of endogenous GLP-1. Bile acids have been shown to induce GLP-1 release via the G protein-coupled bile acid receptor 1 ...

ea0073aep507 | Pituitary and Neuroendocrinology | ECE2021

Treatment regimens affecting glucose metabolism and gastrointestinal hormones in acromegaly: A descriptive study

Nanna Jørgensen , Erichsen Trine , Klose Marianne , Joergensen Morten , Idorn Thomas , Feldt-Rasmussen Bo , Holst Jens J. , Feldt-Rasmussen Ulla

ContextActive acromegaly is associated with impaired glucose metabolism, which improves upon treatment. Treatment options include surgery, medical therapy with somatostatin analogues (SSA) and Pegvisomant (PEG) and in few cases irradiation.ObjectiveTo describe the differential effect of various treatment regimens on the secretion of glucose, insulin, glucagon, glucagon-like peptide-1 (GLP1), and glucose-depen...